UNLABELLED: 3'-Deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) has been used to image tumor proliferation in preclinical and clinical studies. Serial microPET studies may be useful for monitoring therapy response or for drug screening; however, the reproducibility of serial scans has not been determined. The purpose of this study was to determine the reproducibility of (18)F-FLT microPET studies. METHODS: C6 rat glioma xenografts were implanted into nude mice (n = 9) and grown to mean diameters of 5-17 mm for approximately 2 wk. A 10-min acquisition was performed on a microPET scanner approximately 1 h after (18)F-FLT (1.9-7.4 MBq [50-200 muCi]) was injected via the tail vein. A second microPET scan was performed approximately 6 h later on the same day after reinjection of (18)F-FLT to assess for reproducibility. Most of the mice were studied twice within the same week (for a total of 17 studies). Images were analyzed by drawing an ellipsoidal region of interest (ROI) around the tumor xenograft activity. Percentage injected dose per gram (%ID/g) values were calculated from the mean activity in the ROIs. Coefficients of variation and differences in %ID/g values between studies from the same day were calculated to determine the reproducibility after subtraction of the estimated residual tumor activity from the first (18)F-FLT injection. RESULTS: The coefficient of variation (mean +/- SD) for %ID/g values between (18)F-FLT microPET scans performed 6 h apart on the same day was 14% +/- 10%. The difference in %ID/g values between scans was -0.06% +/- 1.3%. Serum thymidine levels were mildly correlated with %ID/g values (R(2) = 0.40). Tumor size, mouse body weight, injected dose, and fasting state did not contribute to the variability of the scans; however, consistent scanning parameters were necessary to ensure accurate studies, in particular, controlling body temperature, the time of imaging after injection, and the ROI size. CONCLUSION: (18)F-FLT microPET mouse tumor xenograft studies are reproducible with moderately low variability. Serial studies may be performed to assess for significant changes in therapy response or for preclinical drug development.
UNLABELLED: 3'-Deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) has been used to image tumor proliferation in preclinical and clinical studies. Serial microPET studies may be useful for monitoring therapy response or for drug screening; however, the reproducibility of serial scans has not been determined. The purpose of this study was to determine the reproducibility of (18)F-FLT microPET studies. METHODS: C6 ratglioma xenografts were implanted into nude mice (n = 9) and grown to mean diameters of 5-17 mm for approximately 2 wk. A 10-min acquisition was performed on a microPET scanner approximately 1 h after (18)F-FLT (1.9-7.4 MBq [50-200 muCi]) was injected via the tail vein. A second microPET scan was performed approximately 6 h later on the same day after reinjection of (18)F-FLT to assess for reproducibility. Most of the mice were studied twice within the same week (for a total of 17 studies). Images were analyzed by drawing an ellipsoidal region of interest (ROI) around the tumor xenograft activity. Percentage injected dose per gram (%ID/g) values were calculated from the mean activity in the ROIs. Coefficients of variation and differences in %ID/g values between studies from the same day were calculated to determine the reproducibility after subtraction of the estimated residual tumor activity from the first (18)F-FLT injection. RESULTS: The coefficient of variation (mean +/- SD) for %ID/g values between (18)F-FLT microPET scans performed 6 h apart on the same day was 14% +/- 10%. The difference in %ID/g values between scans was -0.06% +/- 1.3%. Serum thymidine levels were mildly correlated with %ID/g values (R(2) = 0.40). Tumor size, mouse body weight, injected dose, and fasting state did not contribute to the variability of the scans; however, consistent scanning parameters were necessary to ensure accurate studies, in particular, controlling body temperature, the time of imaging after injection, and the ROI size. CONCLUSION: (18)F-FLT microPET mousetumor xenograft studies are reproducible with moderately low variability. Serial studies may be performed to assess for significant changes in therapy response or for preclinical drug development.
Authors: David C P Cobben; Piet L Jager; Philip H Elsinga; Bram Maas; Albert J H Suurmeijer; Harald J Hoekstra Journal: J Nucl Med Date: 2003-12 Impact factor: 10.057
Authors: Yuan-Chuan Tai; Ananya Ruangma; Douglas Rowland; Stefan Siegel; Danny F Newport; Patrick L Chow; Richard Laforest Journal: J Nucl Med Date: 2005-03 Impact factor: 10.057
Authors: Aren van Waarde; David C P Cobben; Albert J H Suurmeijer; Bram Maas; Willem Vaalburg; Erik F J de Vries; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga Journal: J Nucl Med Date: 2004-04 Impact factor: 10.057
Authors: David C P Cobben; Philip H Elsinga; Albert J H Suurmeijer; Wim Vaalburg; Bram Maas; Piet L Jager; Harald J Hoekstra Journal: Clin Cancer Res Date: 2004-03-01 Impact factor: 12.531
Authors: Ulrike Seitz; Martin Wagner; Bernd Neumaier; Edgar Wawra; Gerhard Glatting; Gerhard Leder; Roland M Schmid; Sven N Reske Journal: Eur J Nucl Med Mol Imaging Date: 2002-06-04 Impact factor: 9.236
Authors: Jennifer G Whisenant; Todd E Peterson; Jacob U Fluckiger; Mohammed Noor Tantawy; Gregory D Ayers; Thomas E Yankeelov Journal: Mol Imaging Biol Date: 2013-02 Impact factor: 3.488
Authors: Jason T Lee; Hanwen Zhang; Maxim A Moroz; Yury Likar; Larissa Shenker; Nikita Sumzin; Jose Lobo; Juan Zurita; Jeffrey Collins; R Michael van Dam; Vladimir Ponomarev Journal: Mol Imaging Biol Date: 2017-02 Impact factor: 3.488
Authors: Toshiro Kitagawa; Hisanori Kosuge; Edwin Chang; Michelle L James; Tomoaki Yamamoto; Bin Shen; Frederick T Chin; Sanjiv S Gambhir; Ronald L Dalman; Michael V McConnell Journal: Circ Cardiovasc Imaging Date: 2013-08-30 Impact factor: 7.792
Authors: Richard G Abramson; Kirsteen R Burton; John-Paul J Yu; Ernest M Scalzetti; Thomas E Yankeelov; Andrew B Rosenkrantz; Mishal Mendiratta-Lala; Brian J Bartholmai; Dhakshinamoorthy Ganeshan; Leon Lenchik; Rathan M Subramaniam Journal: Acad Radiol Date: 2015-01 Impact factor: 3.173
Authors: Michelle S Bradbury; Dolores Hambardzumyan; Pat B Zanzonico; Jazmin Schwartz; Shangde Cai; Eva M Burnazi; Valerie Longo; Steven M Larson; Eric C Holland Journal: J Nucl Med Date: 2008-02-20 Impact factor: 10.057
Authors: M Busk; L S Mortensen; M Nordsmark; J Overgaard; S Jakobsen; K V Hansen; J Theil; J F Kallehauge; F P D'Andrea; T Steiniche; M R Horsman Journal: Eur J Nucl Med Mol Imaging Date: 2012-10-18 Impact factor: 9.236
Authors: Anthony F Shields; Jawana M Lawhorn-Crews; David A Briston; Sajad Zalzala; Shirish Gadgeel; Kirk A Douglas; Thomas J Mangner; Lance K Heilbrun; Otto Muzik Journal: Clin Cancer Res Date: 2008-07-15 Impact factor: 12.531
Authors: Jeffrey R Tseng; Keon Wook Kang; Mangal Dandekar; Shahriar Yaghoubi; Joseph H Lee; James G Christensen; Stephen Muir; Patrick W Vincent; Neil R Michaud; Sanjiv S Gambhir Journal: J Nucl Med Date: 2007-12-12 Impact factor: 10.057